Most Relevant Terms per Topic

Abstracts with Biological Entities (English) - 75 Topics / Sub-Topic Model 51

Topic 1 Topic 2 Topic 3 Topic 4 Topic 5 Topic 6 Topic 7 Topic 8 Topic 9 Topic 10 Topic 11 Topic 12 Topic 13 Topic 14 Topic 15
1 group COVID-19 cold studies bone antibiotics CI participants osteonecrosis dogs cats ribavirin children ® lozenge
2 patients severe common trials SAON care 95 vaccine hip ampligen lung interferon wheezing asthma zinc
3 % HCQ nasal medicine steroid-associated intervention % vaccination corticosteroid calves rfeifn-ω life prednisolone liver lozenges
4 treatment hydroxychloroquine colds chinese rabbits bronchiolitis oseltamivir immunogenicity SARS diarrhea therapy mg/2 episodes LAT AMC/DCBA
5 days patients symptoms evidence marrow trial children MERS ONFH ® 99mtc-mdp rt-pa episode VAS izn
6 study sars-cov-2 upper review expression antibiotic amoxicillin high-dose group hips hemispherx ARDS amantadine balance haemophilia anaesthesia
7 groups 2020 placebo ICWM area bronchitis zanamivir VRC AVN chronic fatigue syndrome parenteral quality exercise sinupret throat
8 = coronavirus infections clinical collapse length azithromycin vaccines femoral fatigue steroid cancer MP LI #
9 compared arbidol symptom herbal model primary exacerbations low-dose group necrosis agreement aes PTE tonsillitis MBP surgery
10 day lpv/r spray WM ANFH dengue presatovir mers-cov steroids neonatal NHM XTJYF recurrent anesthetic kg−1
11 randomized convalescent subjects TCM LPS stay clavulanate seroconversion avascular OIT FES drops system GERD sevoflurane
12 2 standard care iota-carrageenan western steroid-associated osteonecrosis acute bronchitis confidence interval non-adjuvanted head weight nicotine dry STS beriate sufentanil-midazolam
13 received 2019 cold symptoms decongestants antler POCT confidence solicited diagnosis buprenorphine inss mouth antihistamines lobeglitazone CCK
14 < mortality duration search induction feasibility RSV VLP femoral head animals feline quality of life TG PPI nebulised
15 control standard echinacea systematic rabbit magnesium = events imaging biopharma inflammatory bleeding portfolio vs. sore
16 time IVIG extract treatments cells intervention group risk adverse events MRI FA systemic regimen PMC ifn-β atelectasis
17 clinical plasma nasal spray treatment icaritin sample NNTB ™ aspirin ADPP dose ampicillin asthma-like gel PEEP
18 significant mechanical natural clinical trials CON secondary outcomes gargling nitazoxanide resonance mice refractory indomethacin AZT sensitivity active
19 1 chest viruses data MPS sample size paracetamol immune joints calf FCGS dry mouth loaded hepatic 0.1
20 results pandemic influenza-like traditional lipid urtis exacerbation % avascular necrosis excess fluticasone ribavirin therapy strength asthma control μg
21 3 therapy respiratory congestion femoral rhinothermy eps low-dose risk AMI micafungin REFRECARE-H statin NAFLD arterial
22 placebo disease rhinovirus western medicine repair primary care 7630 vaccinations risk factors entered integrative therapy OLP CRP UCVA OTC
23 significantly antiviral viral ID emus fluid bronchiectasis cohorts seizure hemispherx biopharma immunosuppressive biyeom‐go initiation MONT APTT
24 daily treatment volunteers effect femora primary outcome log(10 chadox1 cirrhosis electrolyte PD sleep macrolide genotype-tailored cool
25 methods CHM prep-001 granules src size NNTH SAB-301 magnetic mouse IA response RRTI BIS sensorial
26 adverse ventilation carrageenan meta-analysis extravascular outcomes influenza chadox1 mers arthroplasty tannins salivary aex experimental group CAP hexylresorcinol
27 5 role KRG interventional formation hospital stratified antibody cumulative metoclopramide ciclesonide pegylated spine lignocaine parainfluenza
28 4 negative I-C design showed length of stay D(3 phase withdrawal ringer TB rhifn-α LFX four-factor extubation
29 total EVD population topical group PCT HCQ/CQ high-dose MFON maropitant ciclosporin chronic hepatitis c DXC TTP OC43
30 symptoms CQ virus july PTH hours bias GLS-5300 reference acidosis obstructive low-risk control medication symbicort medetomidine
31 score virus reduced nasal decongestants micro-ct cost URTI subunit CS metabolic acidosis propionate IFN-B motor salbutamol anaesthetic
32 efficacy china ILI sources adipogenesis TRIAL MEDLINE adverse risk factor kakkonto absorption P>0.05 3D values ingredients
33 10 pneumonia inosine chinese medicine vessels REGISTRATION HCT responses AED OES inflammation anemia FHC intention ALI
34 acute observational pranobex reviews CD self-management alleviation MVA-MERS-S magnetic resonance imaging ondansetron treated with herbal therapy CST parameters acute sore throat
35 7 lopinavir/ritonavir ARMS-I planned ablation readiness lymphopenia 0·67 LAOD lactated infants comparator 79 contrast sufentanil
36 control group rapidly tract chinese herbal osteoblasts enrollment AB 319 lesion metabolic INH HFRS g/1000 eye unflavoured
37 - favipiravir antiviral cochrane cell acute prolongation as03-adjuvanted total hip arthroplasty rats hematopoietic oliguria mycoplasma montelukast ICAM-1
38 similar wuhan severity CAM VC myocardial ATP SPR ARCO body weight salvage comparator group internet optivate H2O
39 baseline SOC uris published apoptosis apnea students sub/mf59 plain acute diarrhea discontinued UK-2 LPB immunochemotherapy releasing
40 24 FPV purpurea SARS mirnas length of hospital stay vitamin d(3 P+S harris SC KD UK-12 second-generation lansoprazole u/day
41 30 viral xylometazoline effectiveness ascs TCP adults SCR cm(3 NAC subclinical sustained mobility lacerations emotional
42 trial lopinavir inosine pranobex GLED bilateral femora cineole LOS double doses incidence parvo‐infected united states egyptian PG EDN midazolam
43 statistically significant ebola illnesses 0.00001 H-ICT ethics hrs HAI patients subcutaneous tapered breast cancer first-generation QP non-medicated
44 times influenza illness BF intravascular NUMBER 0.88 humoral HGF chronic obstructive airway disease SS kcal pccs warm
45 recipients coronavirus disease 2019 influenza BLG L-ICT asthma tdp/qt non-adjuvanted group surgical treatment drug biomedicine CRC knee steps rabbits
46 0.001 conversion wind-cold WMD increased physician hospitalisation dose corticosteroid-induced solution inflammatory response breast rhinovirus bleeds pressure
47 frequency ALA hand CLD index medical readiness OZ mg BMD LRS fluticasone propionate pilocarpine cholesterol-lowering exoskeleton heparin
48 points ritonavir flu seasonal influenza rats approval non-severe hemagglutination early syndrome nutrition pain medication T2D ionic
49 end CWB antiwei reduqing head real-time child deemed corticosteroids laboratory concurrent hepatitis experimental singapore prothrombin
50 recommended untreated RV RDQ serum dopamine 0.90 higher hydrocortisone replacer .001 herbal 7000 on‐demand induction